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Post-transplant nephrotic syndrome: A comprehensive clinico-
pathologic study.
Background. Post-transplant (Tx) nephrotic syndrome (NS)
is not well defined.
Methods. Seventy-four renal transplant recipients with NS
were studied.
Results. Biopsies showed chronic allograft nephropathy
(CAN) in 31 patients; recurrent glomerular disease (GN) in 15,
de novo GN in 18, and undetermined GN in 9. NS developed
0.25 to 384 months post-Tx and was treated with angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor
blockers (ARB) in 18 patients; calcium channel blockers in 25;
or both drugs in 31. NS remitted in 24% of cases 2 to 28 months
after onset, and this persisted in all except 3 patients. The re-
mission rate was lowest (9%) for CAN and highest (47%) for
de novo GN. Compared with persistent NS, those with remis-
sion showed higher prevalence of de novo GN (53% vs. 17%),
lower prevalence of CAN (18% vs. 50%), earlier onset of NS
(39 vs. 59 months), lower serum SCr at onset (2.3 vs. 2.9 mg/dL),
and higher incidence of treatment with ACE or ARB. The
5-year graft loss rates for CAN, recurrent and de novo GN were
57%, 36%, and 23%, respectively. Compared with the function-
ing grafts, the failed grafts showed higher prevalence of CAN
(60% vs. 16%), lower prevalence of de novo GN (12% vs. 46%),
earlier onset of NS (47 vs 65 months post-Tx), higher serum SCr
at onset (3.3 vs. 2.0 mg/dL), lower prevalence of remission of
NS (5% vs. 48%), and higher proteinuria at follow-up (5.1 vs.
2.5 g/day). Graft survival improved with NS remission (88% vs.
18%).
Conclusion. Post-Tx NS displays distinctive clinicopathologic
features with pathogenetic and therapeutic implications.
After renal transplantation, up to 43% of recipients de-
velop proteinuria of more than 1 g/day, and up to 13% of
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them develop nephrotic-range proteinuria [1–8]. Among
many factors that can affect renal graft function, protein-
uria of more than 1 g/day is one of the most accurate pre-
dictors of graft loss [9, 10]. Nephrotic-range proteinuria is
known to portend an even worse prognosis, characterized
by a markedly decreased graft survival rate. The one- and
five-year graft survival rates in recipients who develop
post-Tx nephrotic syndrome (NS) are 75.3% and 37.5%,
respectively [3, 4], compared with 87.5% and 52.5% for
those without it [7].
Despite the high incidence and the prognostic impli-
cation of post-Tx NS, many aspects of this syndrome
are not known. There are only a limited number of
pertinent studies, most of which included both patients
with nephrotic and subnephrotic proteinuria, and which
were completed before the introduction of newer im-
munosuppression drugs or international standardization
of nomenclature for the pathologic changes in renal trans-
plant biopsies. In fact, the three major studies of post-Tx
NS covered the periods between the years of 1963–76,
1967–84, and 1980–88, respectively [1, 2, 7]. Almost all
of these studies eliminated cases in which NS developed
shortly after Tx or eventually remitted [1, 2, 6, 5]. Be-
cause of these considerations, many aspects of post-Tx
NS, including its predisposing factors, etiology, associated
renal changes, and clinical course are still not completely
understood. In addition, how the newer immunosuppres-
sive drugs and more recent approaches to the treatment
of proteinuria affect the behavior of post-Tx NS is not
well defined. We undertook this study, which compre-
hensively evaluates all patients with post-Tx NS during a
14-year period, to further characterize this syndrome.
METHODS
Seventy-four cases of post-Tx NS were identified
among the kidney transplant recipients at The Methodist
Hospital/Baylor College of Medicine, Houston, Texas
during a 14-year period from 1988 to 2002. During that
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time there were 570 renal transplant recipients at the
same institute. The clinical follow-up schedule was as
followed: twice weekly for the first 6 weeks, weekly
for the next 6 weeks, biweekly for the next 6 weeks,
triweekly for the next 6 weeks, monthly until the end
of the first year, and bimonthly thereafter. In order to
study the nature of the NS that develops shortly after
Tx, all cases of NS onset were included, regardless of
time.
The urine protein level was measured in 24-hour
collections by a colorimetric method [11], and protein
excretion during the follow-up period was monitored by
the protein/serum creatinine (SCr) ratio in spot morning
urine specimens [12–14]. These methods have been val-
idated previously [12–14]. Routine urinalysis and urine
protein/creatinine ratio was performed for each visit. In
the context of post-Tx proteinuria, renal Tx biopsy was
performed when the urine protein/creatinine ratio con-
tinued to increase in several consecutive follow-up visits,
or when this ratio was more than 1.5. NS was defined as
the presence of edema, protein excretion of more than
3.0 g/day, hypoalbuminemia, and hyperlipidemia.
Seventy-four patients fulfilled these criteria, and their
records were reviewed for clinical features, including
causes of end-stage renal disease (ESRD), donor status,
the course of NS, renal function, conditions that may
be related to the development of NS including blood
pressure, systemic diseases, infections, response to
treatment, and graft outcome. Complete remission of NS
was defined as protein excretion of less than 0.5 g/day
that persisted during at least two consecutive assays
performed at least two weeks apart.
Seventy-three of the 74 patients had at least one trans-
plant biopsy performed within six months of the on-
set of NS to evaluate its causes. Twenty-seven follow-up
biopsies and five graft nephrectomies were performed in
29 patients. The renal transplant biopsies were subjected
to light microscopy (LM) with hematoxylin and eosin,
periodic acid-Schiff (PAS), and Masson’s trichrome
stains; immunofluorescent (IF) studies for immunoglob-
ulin (Ig)G, IgM, IgA, C3, C4, kappa and lambda light
chains, and electron microscopy (EM). The 1997 Banff
classification for renal transplant biopsy [15] was used
for diagnostic categorization. The renal biopsy findings
were tabulated and correlated with the clinical findings
at the time of biopsy and during follow-up.
Differences in proportions were evaluated by chi-
square or Fisher exact test as appropriate. Graft sur-
vival rates were calculated using the method of Kaplan
and Meier, and compared by the log-rank test. Propor-
tional hazards regression model was used for multivariate
analysis of survival. Statistica for Windows software was
used for the statistical analysis (StatSoft, Inc., Tulsa, OK,
USA). Results were considered statistically significant at
P < 0.05.
Table 1. Findings in 73 initial transplant biopsies in 74 patients with
post-transplant nephrotic syndromea
Chronic allograft nephropathy with 31
Nonspecific glomerular changes 13
Chronic allograft glomerulopathy 5
Chronic allograft glomerulopathy + 3
acute glomerulitis
Chronic allograft glomerulopathy + FSGS 4
FSGS 6
Recurrent glomerular diseasesd 15
IgA nephropathy 6
FSGS 4
Membranous GN 2
Diabetic nephropathy 1
Membranoproliferative GN 1
Lupus nephritis 1
De novo glomerular diseased 18
Minimal change disease 5
FSGS 4
Diabetic nephropathy 3
Membranous GNb 2
IgA nephropathy 2
Membranoprliferative GN 1
Proliferative GN 1
Undetermined GN c,d 9
Membranous GNb 4
Proliferative GN 3
IgA nephropathy 2
Total 73
Abbreviations are: GN, glomerulonephritis; FSGS, focal segmental glomeru-
losclerosis.
aTransplant biopsy was not done at time of nephrotic syndrome in 1 patient,
but other features suggested de novo minimal change disease as the cause of
nephrotic syndrome (see text); b1 biopsy showed both de novo membranous GN
and recurrent IgA nephropathy; cthe primary renal diseases were not known
in these cases; dchronic tubulointerstitial injury of variable severity was seen in
many of these biopsies.
RESULTS
Renal transplant biopsies
Because the features of post-Tx NS vary among its
causes, as recognized by renal Tx biopsy findings, these
findings will be described first before reporting the clini-
cal findings and the clinicopathologic correlation.
Initial biopsies
Renal Tx biopsies performed in 73 of 74 patients at
an average of 3.2 months after the onset of NS showed
chronic allograft nephropathy (CAN) in 31, recurrent
glomerular diseases in 15, de novo glomerular diseases in
18, and undetermined glomerulonephritis in 9 patients,
in whom the primary renal diseases were unknown.
The common features of the 31 biopsies with CAN
were tubular atrophy, interstitial fibrosis, interstitial in-
flammation, and fibrous or hyaline intimal thickening of
the arterial blood vessels of variable severity. However,
the glomeruli in these biopsies displayed a spectrum of
lesions (Table 1). Thirteen biopsies showed nonspecific
glomerular changes, including global sclerosis or mild is-
chemic injury characterized by small glomerular size, mild
wrinkling, collapse of the glomerular capillaries, and mild
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focal segmental mesangial sclerosis and hypercellularity.
Twelve biopsies showed chronic allograft glomerulopa-
thy characterized by global or segmental thickening of
the glomerular capillaries, reduplication of the glomeru-
lar basement membrane, and widening of the lamina
rara interna, together with mesangial sclerosis and hy-
percellularity; within this group, focal segmental scle-
rosis of glomeruli was also seen in four biopsies, and
acute glomerulitis in another three biopsies. Six biopsies
showed focal segmental sclerosis involving one or more
glomeruli; some of the glomeruli in these biopsies dis-
played nonspecific changes, as described above, but
chronic allograft glomerulopathy or the vascular changes
characteristic for chronic rejection were not seen.
The 42 biopsies with de novo or recurrent glomeru-
lar diseases (Table 1) displayed features similar to those
diseases in native kidneys. Changes consistent with super-
imposed CAN were also identified in 25 (59%) of these
biopsies. Minimal change disease (MCD) was diag-
nosed in 5 biopsies. These biopsies showed no significant
glomerular changes, except for effacement of foot pro-
cesses; the tubulointerstitial compartment was normal in
three or showed acute rejection and acute cyclosporine
A (CsA) toxicity in one each; remission of NS was a
requirement for the diagnosis of MCD in the present
study.
Biopsy was not performed in one patient in whom NS
developed 2 weeks’ post-Tx, at which time the serum
creatinine (SCr) was 4.4 mg/dL. Antirejection treatment
reversed the SCr to 1.1 mg/dL at one month, but NS
persisted. At 4 months’ post-Tx, the daily protein ex-
cretion was 0.1 g, but the SCr was 3.2 mg/dL and a re-
nal Tx biopsy showed acute cell-mediated rejection and
normal glomeruli. The patient responded to antirejection
therapy, and the NS continued to be in remission until
54 months’ post-Tx, when the SCr was 7.5 and NS re-
curred because of biopsy-documented CAN. Although
the cause of the initial episode of NS is not known, it may
have been related to MCD.
Follow-up biopsies
Twenty-seven follow-up biopsies and five nephrec-
tomies were performed in 29 patients (Table 2). Among
the 17 with the original diagnoses of CAN, the repeated
biopsies still showed CAN, albeit of more advanced de-
gree. The associated glomerular lesions stayed the same
in 12 of these biopsies, but progressed in the other five
(nonspecific glomerular changes to FSGS in one, nonspe-
cific glomerular changes to FSGS and chronic allograft
glomerulopathy in one, FSGS to FSGS with chronic allo-
graft nephropathy in one, and chronic allograft glomeru-
lopathy to chronic allograft nephropathy and FSGS in
one). The diagnosis remained the same for the other
10 repeated biopsies (three recurrent FSGS, two IgA
Table 2. Findings in 27 repeated transplant biopsies and 5
nephrectomy specimens in 29 patients
Original diagnosis Follow-up diagnosis
CAN with nonspecific 3 Same 1
glomerular changes CAN + FSGS + CAG 1
CAN + FSGS 1
CAN with CAG 5 Same 3
CAN + CAG + FSGS 2
CAN with FSGS 6 Same 5
CAN + FSGS + CAG 1
CAN with CAG and 3 Same 3
FSGS
Recurrent FSGSa 3 Same 1
FSGS + more severe 2
chronic TI injury
IgA nephropathy 2 Same 1
IgA nephropathy + more 1
severe chronic TI injury
Membranous GNa 2 Membranous GN + more 2
severe chronic TI injury
Diabetic nephropathy 2 Diabetic nephropathy + more 2
severe chronic TI injury
Lupus nephritis 1 Same 1
(WHO class IV)b
De novo minimal 1 Same 1
change disease
De novo FSGS 1 De novo FSGS + more severe 1
chronic TI injury
Total 29 29
Abbreviations are: CAN, chronic allograft nephropathy; FSGS, focal
segmental glomerulosclerosis; TI, tubulointerstitial; GN, glomerulonephritis;
CAG, chronic allograft glomerulopathy.
aTwo repeated biopsies were done in one of these two cases.
bThree repeated biopsies were done.
nephropathy, two membranous GN, and one each of lu-
pus nephritis, MCD, and de novo FSGS), but the dis-
ease process was more severe in many of these biopsies.
All five nephrectomy specimens showed severe rejection
that obscured the underlying diseases (CAN in three,
IgA nephropathy in one, and diabetic nephropathy in
one).
Clinical findings and clinicopathologic correlations
Patients. The patients included 29 women and 45 men,
with an age range of 16 to 72 years (mean 43). The causes
of ESRD, listed in Table 3, are comparable to those of the
general population, indicating that no specific primary re-
nal disease is predisposed to post-Tx NS. The clinical fea-
tures of patients, separated by the causes of NS, are listed
in Table 4. The cadaveric/living-related donor ratio was
52/22. Six patients had one and three had two previous
renal allografts. Delayed graft function was observed in
14 cases (19%). Hypertension was present in 70 (94%).
The prevalence of hepatitis B infection was 10/48 (21%),
hepatitis C infection 10/44 (23%), and cytomegalovirus
(CMV) seropositivity 30/60 (50%). There was no signifi-
cant difference of the prevalence of these features among
different causes of post-Tx NS.
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Table 3. Original renal diseases in 74 patients
Unknown 14
Diabetic nephropathy 7
Focal segmental glomerulosclerosis 7
Lupus nephritis 9
Hypertensive nephrosclerosis 10
IgA nephropathy 8
Chronic GN 4
Membranous GN 3
Hereditary nephritis 1
Polycystic kidney disease 2
Pyelonephritis 2
Obstructive uropathy 1
Crescentic GN 4
Membranoproliferative GN 2
Total 74
GN is glomerulonephritis.
Features of NS
The time between Tx and onset of NS was widely vari-
able (0.25 to 384 months). However, among different
causes, this interval is shortest for CAN (mean 43.9 vs.
56.7, 57.7, and 81.4 months for other groups, P < 0.001)
(Fig. 1). Thirty-four and 40 cases were encountered in the
first and the second halves of the study period, respec-
tively. At the onset of NS, the daily protein excretion was
similar among groups (mean 5.4, 5.8, 4.8, and 3.9 g/day).
The SCr, however, was highest for CAN (mean 3.6 vs. 2.7,
1.8, and 2.0 mg/dL for other groups).
Treatment
The baseline immunosuppression included CsA,
tacrolimus (FK506), sirolimus (SRL), azathioprine
(AZA), mycophenolate mofetil (MMF), and prednisone
(Pred) in the following combinations: CsA + AZA +
Pred (13 patients), CsA + MMF + Pred [15], CsA +
SRL + Pred [8], FK506 + MMF + Pred [31], SRL + MMF
+ Pred [2], or CsA + Pred [2]. One patient voluntarily
discontinued all immunosuppression 7 years before the
onset of NS [16]. Seventeen patients had acute rejection
before the onset of NS. The types of immunosuppressants
and the incidence of acute rejection were not significantly
different among the causes of post-Tx NS (Table 5).
Treatment for NS included angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin receptor
blockers (ARB) alone (18 patients), calcium channel
blockers (CaCB) alone [25], or both medications [31] and
increased steroid dose alone [1]. Several patients received
these medications for hypertension even before the de-
velopment of NS. Plasmapheresis was used for three out
of four patients with recurrent FSGS.
Remission of NS
At the end of a follow-up of 80 months (range 8 to 420),
complete remission of NS was observed in 17 (23%) of all
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Fig. 1. Graft survival rate after the onset of
transplantation. The impact of the causes of
post-transplant nephrotic syndrome.
cases after a mean of 9.5 months (range 2 to 28), at which
time the mean SCr was 1.7 ± 0.2 mg/dL (range 0.8 to 3.2),
compared to 2.7 ± 0.2 mg/dL (range 0.6 to 12.1) at the on-
set of NS (Table 5). Once the NS underwent remission, the
remission persisted throughout the follow-up period in
all except three patients. In one of the patients, the recur-
rence was caused by biopsy-documented IgA nephropa-
thy with CsA-induced thrombotic microangiopathy, and
it went into remission again until last follow-up, when
the graft remained functional. In the other two patients,
whose initial NS was caused by biopsy-documented and
probable MCD (see earlier text), NS, caused by CAN in
both, recurred 35 and 49.5 months, respectively, after the
initial remission, and it persisted and was associated with
graft loss in both. Table 4 shows that the remission rate
of post-Tx NS differed among its causes and was lowest
(9%) for CAN and highest (47%) for de novo glomerular
diseases (P = 0.016), but there is no difference in the du-
ration of NS among causes. Table 6 illustrates the renal
biopsy findings in cases of NS, which went into remis-
sion. Although MCD was diagnosed in at least 5 biopsies
(30%), a broad spectrum of other lesions was also ob-
served. Compared with cases with persistent NS, those
with remission showed a significantly higher incidence of
de novo GN (53% vs. 17%), a lower incidence of CAN
(17% vs. 49%), an earlier onset of NS (39 vs. 59 months),
a lower SCr at the onset of NS (2.3 vs. 2.9 mg/dL), and a
higher incidence of a treatment which included ACE or
ARB. A multivariate analysis showed, however, that re-
mission was independently associated only with etiology
(P = 0.002).
Graft outcome
The mean duration of follow-up was 80 months (range
8 to 420), with that for CAN group significantly shorter
than those of the other groups. This difference mainly re-
flects the time of graft loss as end point, and there were
more graft losses in the CAN group. Four patients died
of nonrenal causes during the follow-up. At the end of
follow-up, 31 grafts (42%) remained functional, and 43
(58%) failed after a mean of 21.9 months (range 1 to
63) after the onset of NS. Graft loss was most frequent
(Fig. 1) and earliest (Fig. 2) for CAN, followed by those
associated with recurrent and de novo glomerular dis-
eases. The five-year graft loss rates for CAN, recurrent,
and de novo glomerular diseases were 57%, 36%, and
23%, respectively. The mean duration between the on-
set of NS and graft loss was 14.4, 33.6, and 40.3 months
for CAN, recurrent, and de novo glomerular diseases,
respectively. Although the rate of graft loss for the un-
determined GN approached that of CAN, in three out of
four lost grafts in this group there was advanced CAN
in addition to GN. Compared with the functioning grafts
(Table 7), the failed grafts showed a significantly higher
incidence of CAN (60% vs. 16%), a lower incidence
of de novo GN (12% vs. 46%), an earlier onset of NS
(47 vs. 64 months post-Tx), a higher SCr at the onset of
NS (3.3 vs. 2.0 mg/dL), a lower incidence of remission
of NS (5% vs. 48%), and a higher protein excretion at
follow-up (5.1 vs. 2.5/day). Figure 3 shows that, regard-
less of the cause of NS, the rate of graft survival was sig-
nificantly better in those in whom the NS remitted (P =
0.004). In the multivariate analysis of factors influencing
Yakupoglu et al: Post-transplant NS: Clinicopathologic study 2365
Table 5. Outcome of post-transplant nephrotic syndrome
Remission Persistence
N = 17 N = 57 P value
Cause of NS
CAN 3 (18%) 28 (50%)
Recurrent glomerular diseases 4 (23%) 11 (19%)
De novo glomerular diseases 9 (53%) 10 (17%)
Undertermined GNa 1 (6%) 8 (14%) =0.01
Age years 41.1 ± 4.0 43.1 ± 1.6 >0.05
(16–68) (22–72)
F/M ratio 6/11 23/34 >0.05
Cadaveric/living donors 12/5 40/17 >0.05
Months between Tx and NS 39.3 ± 12.0 59.5 ± 9.7 >0.05
(0.25–156) (1–384)
Pro at biopsy g/day 4.7 ± 0.4 5.3 ± 0.4 >0.05
(3.1–8.9) (3–16)
SCr at biopsy mg/dL 2.3 ± 0.6 2.9 ± 0.2 >0.05
(0.6–12.1) (1–6.8)
Treatment for NS
ACEI or ARB 7 (39%) 11 (19%)
ACEI or ARB + CaCB 8 (44%)b 23 (40%)
CaCB only 3 (17%) 22 (39%)
None 1 (2%) >0.05
Months between onset and 9.9 ± 1.7 >0.05
remission of NS
(2–28)
Pro at remission of NS g/day 0.2 ± 0.04 >0.05
(0.0–0.6)
SCr at remission of NS mg/dL 1.7 ± 0.2 >0.05
(0.8–3.2)
Follow-up months 73.9 ± 13.0 81.9 ± 10.6 >0.05
(11–192) (8–420)
Pro at follow-up g/day 0.8 ± 0.5 5.0 ± 0.4 =0.001
(0–8) (1.5–16)
SCr at follow-up mg/dL 2.3 ± 0.5 5.4 ± 0.5 =0.001
(0.8–8.5) (1.1–19.9)
Graft failure 2 (12%) 41 (72%)
Months between NS and graft 23.2 ± 3.1
failure (2–89)
Abbreviations are: ACEI, angiotensin-converting enzyme inhibitors; ARB,
angiotensin receptor blockers; Bx, biopsy; CaCB, calcium channel blockers;
CAN, chronic allograft nephropathy; F/M, female/male; GN, glomerulonephritis;
NS, nephrotic syndrome; Pro, proteinuria; Scr, serum creatinine; Tx, transplant.
aThe primary renal diseases were not known in these cases; bOne patient had
two reversible episodes of post-transplant nephrotic syndrome.
graft survival, only etiology of NS had an independent
prognostic value (P < 0.001).
DISCUSSION
The present study reporting post-Tx NS in 13%
(74/570) of renal transplant recipients indicates that this
is a frequent condition. This incidence, which is higher
than reported in most previous studies with a range be-
tween 3% to 13.7% [17, 18], may be related to study
design because our study included all patients with post-
Tx NS, whereas only those in whom the NS persisted or
developed beyond 1 to 3 months post-Tx were included in
previous studies [1, 2, 18]. NS developed within 3 months
post-Tx in 14 patients in our study and, if these cases
were eliminated, the incidence of post-Tx NS would be
10.5%. These observations indicate that the incidence of
post-Tx Ns remains the same over the years, in spite of
Table 6. Tranplant biopsy findings in 17 episodes of reversible
post-transplant nephrotic syndromea
CAN 3
with nonspecific glomerular changes 1
with acute glomerulitis 2
Recurrent glomerular diseases 5
IgA nephropathyc + acute glomerulitis 1
IgA nephropathyc + thrombotic microangiopathyb 1
FSGS + acute rejection 1
Membranous GN + acute glomerulitis 1
Lupus nephritis + acute rejection 1
De novo glomerular diseases 8
Minimal change disease + acute rejection 1
Minimal change disease + acute CsA nephrotoxicity 1
Minimal change disease 3
IgA nephropathy 1
Diabetic nephropathy 1
FSGS 1
Undetermined glomerular diseased 1
Membranous GN 1
Abbreviations are: CAN, chronic allograft nephropathy; CsA, cyclosporine
A; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis.
aThere were 17 patients with 18 episodes of reversible NS, but biopsy was not
done in 1 episode.
bThrombotic microangiopathy may be related to superimposing acute CsA
nephrotoxicity.
cThese 2 biopsies were from 2 different episodes of reversible nephrotic
syndrome in 1 patient.
dThe primary renal disease was not known in this case.
newer immunosuppression regimens and better control
of acute rejection. In fact, our study shows no significant
difference in the frequencies of NS between the 1988 to
1994 (34 cases) and 1995 to 2002 periods (40 cases), and
among different immunosuppression groups.
Most previous studies concur that post-Tx NS caused
by recurrent glomerular diseases, de novo glomerular
diseases, and a heterogeneous but related group of re-
nal injury unrelated to the former two, for which sev-
eral names, including transplant glomerulopathy, chronic
rejection, CsA vasculopathy, and allograft glomerulopa-
thy have been used [1–8]. Among these studies, the same
name was used to describe different lesions, or the same
lesion was reported under different names. This confu-
sion has detracted from a uniform understanding of the
real causes of post-Tx NS, as well as the frequency and
the biologic significance of these causes.
In the present study, the widely accepted terminol-
ogy from the 1977 Banff classification on the pathologic
changes of renal allografts was used [15]. According to
this classification, CAN is the most frequent cause of post-
Tx NS (40%) in our study. These observations corrobo-
rate those reported in previous major studies on post-Tx
NS, and indicate that its general causes remained the same
over the years [1, 2, 7]. Because heavy proteinuria is well
known to reflect glomerular injury, the types of glomeru-
lar lesion seen in CAN were carefully documented and
classified in the present study (Table 1). We could not find
any clinical difference among these glomerular lesions,
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Fig. 2. Graft survival rate after the onset of
nephrotic syndrome. The impact of its causes.
Table 7. Graft outcome
Failed Functioning
grafts grafts
(N = 43) (N = 31) P value
Cause of NS
CAN 26 (60%) 5 (16%)
Recurrent glomerular diseases 8 (19%) 7 (22%)
De novo glomerular diseases 5 (12%) 14 (46%)
Undetermined GNa 4 (9%) 5 (16%) =0.0007
Age 41.5 ± 1.9 45.0 ± 2.5 >0.05
(22–72) (16–68)
F/M ratio 17/26 12/19 >0.05
Cadaveric/living donors 30/13 22/9 >0.05
Months between Tx and NS 47.0 ± 7.3 64.9 ± 15.9 >0.05
(1.5–130) (0.25–384)
Pro at biopsy g/day 5.4 ± 0.4 4.8 ± 0.3 >0.05
(3–16) (3.1–8.9)
SCr at biopsy mg/dL 3.3 ± 0.3 2.0 ± 0.3 >0.05
(0.9–6.8) (0.6–12.1)
Treatment for NS
ACEI or ARB 8 (19%) 10 (31%)
ACEI or ARB + CaCB 17 (39%) 14 (44%)
CaCB only 17 (39%) 8 (25%)b
None 1 (3%) 0 (0%) >0.05
Cases with remission of NS 2 (5%) 15 (48%) <0.001
Months between NS and 21.9 ± 3.6
graft failure
(1–63)
Follow-up months 69.3 ± 8.2 95.5 ± 17.4 >0.05
(8–161) (11–420)
Pro at follow-up g/day 5.1 ± 0.4 2.5 ± 0.6 =0.031
(0.4–14) (0.0–16)
SCr at follow-up mg/dL 6.7 ± 0.5 1.8 ± 0.1 =0.031
(2.8–19.9) (0.8–2.9)
Abbreviations are: ACEI, angiotensin-converting enzyme inhibitors; ARB,
angiotensin receptor blockers; Bx, biopsy; CaCB, calcium channel blockers; CAN,
chronic allograft nephropathy; F/M, female/male; GN, glomerulonephritis; NS,
nephrotic syndrome; Pro, proteinuria; SCr, serum creatinine; Tx, transplant.
aThe primary renal diseases were not known in these cases.
bOne patient had 2 separate episodes of nephrotic syndrome.
indicating that NS is related to the severe renal injury
typical for CAN, rather than a specific type of glomerular
lesion encountered in this condition.
De novo and recurrent glomerular diseases were
confirmed by this study as the other causes of post-
Tx NS (26% and 20%, respectively). De novo FSGS
can be seen in renal transplant in at least two differ-
ent contexts: (1) as a component of chronic allograft
glomerulopathy; or (2) as an isolated finding, which may
be associated with mild chronic tubulointerstitial injury,
but without obvious features chronic allograft glomeru-
lopathy [19–22]. Whether these two categories are re-
lated or independent entities remains controversial. We,
however, are convinced that FSGS unrelated to chronic
allograft glomerulopathy may occur. This condition is
characterized by focal segmental sclerosis of glomeruli,
associated with no significant or only minor nonspecific
changes in the remaining glomeruli, absence of features
of chronic allograft glomerulopathy, absence of the type
of vascular lesions characteristic for vascular chronic re-
jection, and mild-to-moderate chronic tubulointerstitial
nephritis. It may be clinically manifested by nephrotic-
range proteinuria with mild impairment of renal func-
tion. Six such cases were encountered in our studies, and
one of them was previously reported [16]. This type of
FSGS has also been alluded to in previous reports on
post-Tx FSGS [19–22]. Recognizing this type of lesion
may be in keeping with the current thought that chronic
glomerular injury in renal transplants may be multifacto-
rial [15]. It may be a result of an immunologic response,
which would account for the development of chronic al-
lograft glomerulopathy with focal segmental sclerosis of
glomeruli as a component [20–22]. Alternatively, other
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Fig. 3. Graft survival rate. Impact of per-
sistence versus remission of the nephrotic
syndrome.
conditions, including hyperfiltration, reflecting the pres-
ence of a single kidney with potential further impairment
by factors such as advanced donor’s age, pretransplant
ischemia, donor-related nephrosclerosis, or cyclosporine
A–induced arteriolopathy may account for the type of
FSGS unrelated to an alloreactivity [23]. IgA nephropa-
thy was diagnosed in two patients whose primary diseases
were FSGS and hypertensive nephrosclerosis, respec-
tively. Donor-related IgA nephropathy is quite frequent
and was reported in 11% and 5.4% of living-related and
cadaveric donors, respectively [24, 25]. Without a donor
renal biopsy, it is not possible to conclusively determine
whether the IgA nephropathy in these two patients was
de novo or donor-transmitted. However, several stud-
ies have suggested that kidneys with donor-transmitted
IgA nephropathy function well and, indeed, IgA disap-
pears a few months post-Tx in repeated biopsies [26–29].
These considerations suggest that the IgA nephropathy
in these two patients was probably de novo. MCD was
biopsy-documented in 5 cases (7%), and probably was
the cause of NS in another (see earlier text). Some of
these cases were previously reported in more detail [30].
These cases share the same clinicopathologic features, in-
cluding a lack of significant glomerular changes, except
for effacement of the foot processes, a lack of chronic
tubulointerstitial injury, an early onset of NS (1 week
to 4 months post-Tx), a normal or mildly decreased re-
nal function which was readily reversed by antirejection
treatment or decreased CsA dose, sustained remission
of NS, and functioning grafts at last follow-up. Several
isolated cases with features similar to ours have been re-
ported (reviewed in [30]), and MCD accounted for 2.7%
(1/36) [1], 4% (1/26) [31], and 5.5% (1/18) [32] in three
series of post-Tx NS. Several renal lesions in the early
post-Tx period (usually defined as one month), including
preservation injury, acute tubular necrosis, or acute re-
jection may induce proteinuria but spare glomeruli and
thus can be confused with MCD on biopsy. However,
the proteinuria in these conditions is usually mild (less
than 1 g/day) and should decrease rapidly in the follow-
ing weeks, with complete remission in most cases within a
month [33–36]. Furthermore, MCD developed in living-
related grafts in two current and at least five previously
reported cases [1, 37–41], in which preservation injury or
acute tubular necrosis was unlikely. MCD in native kid-
ney may be related to undetermined circulating factors,
probably lymphokines, which promote transglomerular
capillary permeability [42]. Disturbed immunoregulation
in renal allograft recipients may lead to activation of se-
lected population of lymphoid cells capable of synthesiz-
ing the lymphokine(s) responsible for NS [43]. Although
the patients with post-Tx MCD were on several medica-
tions, the same types of medication were also used for
renal transplant recipients without post-Tx NS or those
in whom the post-Tx NS was not caused by MCD. These
observations suggest that post-Tx MCD is probably not
iatrogenic. These observations suggest that although the
nature of de novo MCD is not known, it represents an
important but previously underemphasized cause of post-
TX NS, with a characteristic clinicopathologic profile in-
cluding a uniformly good prognosis.
The treatment for post-Tx NS syndrome has not been
established. Although inhibition of the renin-angiotensin
system with ACEI or ARB has been known to atten-
uate proteinuria associated with native kidney diseases,
especially diabetic nephropathy, its role in the treatment
of post-Tx proteinuria has just recently been explored,
and the pertinent studies focus on significant but mild
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proteinuria rather than NS. Dulek et al demonstrated that
a 12-week treatment with losartan reduced microalbu-
minuria in hypertensive renal transplant recipients from
a mean of 103 to 47 mcg/min [44]. Suwelack et al showed
in a similar group of patients a stable mean protein excre-
tion of 0.52 g/day over a five-year period with quinapril,
compared with an increase in protein excretion from 0.34
to 0.72 g/day in those treated with a beta blocker [45]. An-
tiparmarek et al reported a rate of 75% partial or total
remission in 37 renal transplant recipients with protein
excretion of 1 g or more a day in response to ACE or
ARB. In all these studies, the antiproteinuric effect of
ACE or ARB was independent of blood pressure [46]. In
contrast, although CaCB has been shown to control post-
Tx hypertension and improve graft survival in both clin-
ical and experimental settings [47, 48], protein excretion
under this regimen was not attenuated, but was actually
increased. Sixty-five percent of the patients in the current
study were treated with ACEI or ARB, without (24%) or
with (41%) CaCB, whereas 33% of them received CaCB
only. ACEI/ARB was used more frequently than CaCB
in patients with remission (83% vs. 17%), compared with
those in whom the NS persisted (60% vs. 38%). These
observations suggest that pharmacologic inhibition of the
renin-angiotensin system may attenuate post-TX protein
excretion, regardless of its magnitude.
Remission of post-Tx NS caused by recurrent FSGS,
the most frequent cause of this syndrome in pediatric
population, has been well studied, and this outcome was
reported in up to 50% of cases [49–51]. However, little
is known about the remission of post-Tx NS resulting
from other causes. There are only isolated reported cases
in which post-Tx NS caused by de novo MCD [30], acute
glomerulitis [52, 53], acute rejection [7, 53], chronic rejec-
tion [7], de novo or recurrent membranous GN [54–56],
or foscarnet-induced GN [57] underwent remission. Most
series on post-Tx proteinuria/NS included only cases with
persistent proteinuria [2, 5, 6, 18, 31]. Because of these
considerations, the features of the subset of post-Tx NS
that is destined to undergo remission are not known. The
current study found that post-Tx NS underwent remis-
sion in 23% of all cases, several of which were reported
in detail elsewhere [58]. This incidence is between those
mentioned briefly by Vathsala et al (11.3%) and Yildiz
et al (47%), which, to the best of our knowledge, are the
only two studies providing these data [7, 8]. The collec-
tive observations suggest that remission of post-Tx NS is
not unusual. As reported previously, we found no signifi-
cant differences in the age, sex, spectrum of primary renal
diseases, cadaveric/living-related donor ratio, or the fre-
quency of hypertension, hepatitis B, hepatitis C, or CMV
seropositivity, or the immunosuppression regimens be-
tween patients in whom the NS persisted or remitted [58].
However, these two groups did show differences in the
renal biopsy findings, the onset of NS, the treatment for
NS, and the chance of graft survival. The NS, which un-
derwent remission, had an earlier onset than those that
persisted (mean 39.3 vs. 59.5 months) and, in fact, the on-
set was within three months post-Tx in 47% of the cases.
These observations indicate that early onset is an impor-
tant predictor of remission. The renal biopsy findings are
another important predictor of remission because recur-
rent or de novo glomerular diseases are significantly more
frequent in the remitted group as compared with the per-
sistent one (47% vs. 17%, P = 0.031), and almost a half
and a third of cases of NS caused by recurrent and de
novo glomerular diseases, respectively, underwent remis-
sion Although a spectrum of renal lesions was found to be
associated with remission (Table 6), MCD encountered
in five cases (30%) is the most frequent one and the early
onset of remitted NS largely reflects the predominance of
MCD within this time frame (Table 7). The remission of
NS encountered in all cases of MCD may be akin to the
behavior of the same disease in the native kidney [59].
The remission of NS in one out of four cases of recurrent
FSGS (25%) reflects the known behavior of NS associ-
ated with this condition, and may be related to therapy
including plasmapheresis to remove a putative circulating
glomerular permeability factor suspected to be of patho-
genetic importance for FSGS in general [49, 50]. On the
other hand, how the NS associated with other diseases
listed in Table 6 underwent remission is not clear because
the NS associated with these diseases is in general per-
sistent. Several Tx biopsies in these cases showed acute
glomerulitis or acute cell-mediated rejection, in addition
to the main glomerular lesions. It is possible that acute
glomerulitis or acute rejection, which by itself has been
reported to be associated with mild and infrequent pro-
teinuria [7, 52, 53], may accentuate the proteinuric effect
of other glomerular lesions. Because they are reversible in
response to immunosuppression, their presence may be
partly responsible for the remission of NS. Alternatively,
remission may be related to treatment because most of
these patients were treated with ACEI and/or ARB. One
interesting feature of the remitted NS is that the remission
continued in the vast majority of cases, and this predicted
a far superior graft outcome as compared with the persis-
tent group (2-, 5- and 10-year graft survivals: 100%, 82%,
and 82% vs. 83%, 54%, and 25%). These observations
corroborate previous reports [3, 5, 6, 7] and support re-
cent multivariate analyses, which showed that, among nu-
merous factors which can influence renal graft outcome,
heavy proteinuria is the most [10] or the second most
(behind arterial resistance) important [9].
CONCLUSION
The overall five-year graft loss rate of 48% in our study
(Fig. 1) was somewhat better than those previously re-
ported, which ranged from 60% to 77% [1, 2, 7]. This
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difference, however, may be caused by the inclusion of
those with remission of NS because if they are eliminated
the rate was 56% (Fig. 2). These observations indicate
that the risk of graft loss incurred by persistent post-Tx
NS has not improved over the years. Although post-Tx
NS portends poor graft outcome in general, our study sug-
gests the prognosis is quite different among subgroups of
patients. Apart from the general agreement that remis-
sion of proteinuria implies a good outcome [3, 5, 6, 7],
the impact of other factors remains in dispute. Cheigh
et al originally suggested that recurrent GN carried the
worst prognosis, followed by “allograft glomerulopathy”
and de novo GN [1]. Vatsala et al reported a worse prog-
nosis for the “non GN” than the “GN” group [7]. Peddi
et al and First et al found no difference in graft survival
among causes of post-Tx heavy proteinuria [2, 6]. Our
study provides strong evidences to suggest that the two
most important prognostic factors for post-Tx NS are its
causes and whether it remits or persists. Among the dif-
ferent causes of post Tx NS, CAN is associated with the
highest rate of graft loss (84%), the lowest rate of remis-
sion (9%), and the shortest duration (14.4 months) from
the onset of NS to graft loss (Table 4 and Fig. 1). Although
poor graft survival in our study was significantly associ-
ated with an early onset of NS, a higher SCr level at onset
of NS, and the severity of chronic tubulointerstitial injury,
these factors were also most pronounced for CAN, and
they may not be independent predictors, as shown by a
multivariate analysis.
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